Orbis will work with Amazon's cloud computing arm to expand access to artificial intelligence-assisted eye screenings in Asia and Africa.
NEW YORK, Dec. 18, 2023 /PRNewswire/ -- Eye care nonprofit Orbis International announces it has been selected as a winner of the 2023 Amazon Web Services (AWS) IMAGINE Grant, a public grant opportunity open to registered 501(c) nonprofit organizations in the United States and the United Kingdom who are using technology to solve the world's most pressing challenges. The grant will support Orbis's efforts to deploy its artificial intelligence (AI)-assisted technology in low-resource areas to screen for two eye diseases that lead to irreversible blindness, diabetic retinopathy and glaucoma. This technology will redefine what is possible during vision screening processes for communities in low- and middle-income countries.
Now in its sixth year, the AWS IMAGINE Grant program provides vital resources to nonprofit organizations looking to deploy cloud technology as a central tool to achieve mission goals. As part of the program, AWS seeks proposals for big ideas on how to leverage technology in new and innovative ways to accelerate impact in local and global communities. Since the launch of the IMAGINE Grant program in 2018, AWS has awarded over $7M in unrestricted funds, AWS Promotional Credits, and AWS training support to 89 nonprofit organizations in support of their technology-driven goals.
"Cybersight AI, Orbis's state-of-the-art technology, is a proven, effective and accessible technology to screen for diabetic retinopathy and glaucoma," said Nicolas Jaccard, Orbis Principal Architect, Telehealth and Program Technology. "The tool analyzes images of the back of the eye and, within seconds, indicates whether the patient shows signs of glaucoma or diabetic retinopathy. This technology is more scalable, cheaper and faster than current models that require a human grader. With this grant, Orbis will expand this revolutionary tool to more areas without access to quality eye care."
Recent Orbis studies show Cybersight AI leads to patients' increased uptake of referral services and high levels of satisfaction. The technology has also been shown to be equally effective for children with diabetes as it is for adults. Over the past three years, using AWS cloud services, Orbis built Cybersight AI and deployed the technology in partner hospitals in Rwanda and Vietnam. Now, with expanded support from AWS, Orbis is establishing a new instance of Cybersight AI in the AWS Africa (Cape Town) region, which will provide improved performance for clinics across Africa.
The support from AWS will also refine existing and add new capabilities. Cybersight AI will be trained to take advantage of new, larger, and more diverse datasets, ensuring the most accurate results. The project will also add the detection of a third eye disease, diabetic macular edema, another leading cause of vision loss in people with diabetes.
Orbis's democratization of AI is revolutionary – providing real-time, automated clinical advice at no cost to health facilities and their patients in low- to middle-income countries. The cost of AI-enabled healthcare platforms is typically too expensive for care providers in these communities. Due to its scalability, Cybersight AI has the potential to become the default screening method in low- to middle-income countries.
Jean, a 19-year-old with diabetes in Kigali, Rwanda, recently had his eyes screened at the Rwanda Diabetes Association clinic using Cybersight AI technology. He was relieved to know immediately that he was not showing any signs of disease. Of learning the news, he said, "I will continue taking care of myself and following the recommendation from my health care worker so my eyes don't get damaged from the diabetes."
Diabetic retinopathy is now the leading cause of vision loss in working-age adults, and glaucoma is the leading cause of irreversible blindness worldwide. Ensuring more people with these conditions have access to early detection and intervention is key to saving sight for millions of people.
For example, timely treatment of diabetic retinopathy can reduce the risk of vision loss by as much as 98%. However, early detection and intervention are often thwarted by insufficient human resources for eye health, a lack of trained specialists to assess retinal images and limited patient access – challenges that AI screenings can help communities overcome. The health, education and economic impact of vision loss is devastating, particularly for people in the poorest communities. Continued investment and innovation in eye care is urgent.
About Orbis
Orbis is an international nonprofit delivering sight-saving programs in over 200 countries and regions worldwide so that individuals, families, and communities can thrive. Currently, around 1 billion people across the globe live with completely avoidable blindness and vision loss. For over four decades, Orbis has been tackling this challenge by building strong and sustainable eye care systems that leave a lasting legacy of vision. Orbis runs dedicated in-country programs in Africa, Asia, the Caribbean, and Latin America; develops and implements innovative training and technology, including an award-winning telemedicine and e-learning platform, Cybersight; and operates the world's first and only Flying Eye Hospital, a fully accredited ophthalmic teaching hospital on board an MD-10 aircraft. For the past ten consecutive years, Orbis has achieved Charity Navigator's coveted four-star rating for demonstrating strong financial health and commitment to accountability and transparency, placing Orbis in the top 3% of U.S. charities. For the past two years, Orbis has earned GuideStar's platinum Seal of Transparency. In 2022, Orbis earned "accredited charity" status from the Better Business Bureau by meeting all 20 of their standards for charity accountability. To learn more, please visit orbis.org.
MEDIA CONTACT Orbis International Jenna Montgomery Manager, Global Communications and Marketing [email protected]
SOURCE Orbis International
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Share this article